Pharmacologic, biologic, and genetic engineering approaches to potentiation of donor-derived dendritic cell tolerogenicity

P. Toby H. Coates, Bridget L. Colvin, Katsuhiko Kaneko, Timucin Taner, Angus W. Thomson

Research output: Contribution to journalArticle

32 Scopus citations

Abstract

There are various approaches to the enhancement of dendritic cell (DC) tolerogenicity for the promotion of cell or organ allograft survival. Both pharmacologic and biologic agents, including several commonly used immunosuppressive drugs, and specific anti-inflammatory cytokines inhibit DC maturation, whereas costimulation-blocking agents can also promote the induction of antigen-specific T-cell unresponsiveness by DC. Delivery of genes encoding molecules that subvert T-cell responses by various mechanisms, and targeting of DC migration by selective manipulation of chemokine and chemokine receptor expression, represent additional promising strategies. In this short review, the authors consider those approaches that have been used to promote the tolerogenicity of donor-derived DC in experimental models. Whereas most work to date has focused on myeloid DC, manipulation of other DC subsets may also offer potential for improving the outcome of transplantation and enhancing tolerance induction.

Original languageEnglish (US)
Pages (from-to)32S-36S
JournalTransplantation
Volume75
Issue number9 SUPPL.
StatePublished - May 15 2003

ASJC Scopus subject areas

  • Transplantation

Fingerprint Dive into the research topics of 'Pharmacologic, biologic, and genetic engineering approaches to potentiation of donor-derived dendritic cell tolerogenicity'. Together they form a unique fingerprint.

  • Cite this